

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): October 17, 2017**

---

**PIERIS PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Nevada**  
(State of Incorporation)

**001-37471**  
(Commission  
File Number)

**EIN 30-0784346**  
(IRS Employer  
Identification No.)

**255 State Street, 9th Floor**  
**Boston, MA 02109**  
(Address of principal executive offices, including zip code)

**Registrant's telephone number, including area code: 857-246-8794**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 7.01 Regulation FD Disclosure.**

Pieris Pharmaceuticals, Inc. announced today that it has enrolled the first patient in its multi-dose Phase IIa study of PRS-080, Pieris' Anticalin® protein targeting hepcidin, in functional iron deficiency (FID) anemic patients with chronic kidney disease undergoing hemodialysis. The Company is conducting this Phase IIa study in Germany and the Czech Republic where it previously filed separate clinical trial applications (CTAs) with the relevant regulatory authorities. The study will be conducted in a randomized, placebo-controlled manner with two dose cohorts of 4 mg per kg and 8 mg per kg body weight, with 4 patients receiving drug at each dosage level and 2 patients on placebo within each cohort.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including the exhibits attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 17, 2017

**PIERIS PHARMACEUTICALS, INC.**

By: /s/ Allan Reine

Name: Allan Reine

Title: Chief Financial Officer